Biomed & Biotech Firms - Publicly Traded*

Neurocrine Biosciences Inc.

Company Website

12790 El Camino Real
San Diego, CA 92130

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Neurocrine Biosciences Inc.

Market Cap as of 6/12/2015

$3,716,528,384

Market Cap as of 7/03/2014

$1,191,049,633

Market Cap as of 07/02/2013

$907,560,242

Market Cap as of 06/26/2012

$521,167,908

Market Cap as of 01/04/2012

$459,735,600

Market Cap as of 06/20/2011

$405,172,000

Market Cap as of 01/06/2011

$412,538,300

Exchange and Ticker Symbol

Nasdaq: NBIX

Fields of Research

Discovery, development and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders

Major Products

Elagolix; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2); CRF2 Peptide Agonist; CRF1 Antagonist; G Protein-Coupled Receptor 119 (GPR119); VMAT2; GnRH Antagonists; Antiepileptic Drugs; G Protein-Coupled Receptors

Executives

Kevin Gorman

  • Chief Executive Officer
  • President